Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial)

Emma J Eshuis, Willem A Bemelman, Ad A van Bodegraven, Mirjam A G Sprangers, Patrick M M Bossuyt, A W Marc van Milligen de Wit, Rogier M P H Crolla, Djuna L Cahen, Liekele E Oostenbrug, Meindert N Sosef, Annet M C J Voorburg, Paul H P Davids, C Janneke van der Woude, Johan Lange, Rosalie C Mallant, Maarten J Boom, Rob J Lieverse, Edwin S van der Zaag, Martin H M G Houben, Juda Vecht, Robert E G J M Pierik, Theo J M van Ditzhuijsen, Hubert A Prins, Willem A Marsman, Henricus B Stockmann, Menno A Brink, Esther C J Consten, Sjoerd D J van der Werf, Andreas W K S Marinelli, Jeroen M Jansen, Michael F Gerhards, Clemens J M Bolwerk, Laurents P S Stassen, B W Marcel Spanier, Ernst Jan Spillenaar Bilgen, Anne-Marie van Berkel, Huib A Cense, Henk A van Heukelem, Arnold van de Laar, Warner Bruins Slot, Quirijn A Eijsbouts, Nancy A M van Ooteghem, Bart van Wagensveld, Jan M H van den Brande, Anna A W van Geloven, Karien F Bruin, John K Maring, Bas Oldenburg, Richard van Hillegersberg, Dirk J de Jong, Robert Bleichrodt, Donald L van der Peet, Pascal E P Dekkers, T Hauwy Goei, Pieter C F Stokkers, Emma J Eshuis, Willem A Bemelman, Ad A van Bodegraven, Mirjam A G Sprangers, Patrick M M Bossuyt, A W Marc van Milligen de Wit, Rogier M P H Crolla, Djuna L Cahen, Liekele E Oostenbrug, Meindert N Sosef, Annet M C J Voorburg, Paul H P Davids, C Janneke van der Woude, Johan Lange, Rosalie C Mallant, Maarten J Boom, Rob J Lieverse, Edwin S van der Zaag, Martin H M G Houben, Juda Vecht, Robert E G J M Pierik, Theo J M van Ditzhuijsen, Hubert A Prins, Willem A Marsman, Henricus B Stockmann, Menno A Brink, Esther C J Consten, Sjoerd D J van der Werf, Andreas W K S Marinelli, Jeroen M Jansen, Michael F Gerhards, Clemens J M Bolwerk, Laurents P S Stassen, B W Marcel Spanier, Ernst Jan Spillenaar Bilgen, Anne-Marie van Berkel, Huib A Cense, Henk A van Heukelem, Arnold van de Laar, Warner Bruins Slot, Quirijn A Eijsbouts, Nancy A M van Ooteghem, Bart van Wagensveld, Jan M H van den Brande, Anna A W van Geloven, Karien F Bruin, John K Maring, Bas Oldenburg, Richard van Hillegersberg, Dirk J de Jong, Robert Bleichrodt, Donald L van der Peet, Pascal E P Dekkers, T Hauwy Goei, Pieter C F Stokkers

Abstract

Background: With the availability of infliximab, nowadays recurrent Crohn's disease, defined as disease refractory to immunomodulatory agents that has been treated with steroids, is generally treated with infliximab. Infliximab is an effective but expensive treatment and once started it is unclear when therapy can be discontinued. Surgical resection has been the golden standard in recurrent Crohn's disease. Laparoscopic ileocolic resection proved to be safe and is characterized by a quick symptom reduction. The objective of this study is to compare infliximab treatment with laparoscopic ileocolic resection in patients with recurrent Crohn's disease of the distal ileum with respect to quality of life and costs.

Methods/design: The study is designed as a multicenter randomized clinical trial including patients with Crohn's disease located in the terminal ileum that require infliximab treatment following recent consensus statements on inflammatory bowel disease treatment: moderate to severe disease activity in patients that fail to respond to steroid therapy or immunomodulatory therapy. Patients will be randomized to receive either infliximab or undergo a laparoscopic ileocolic resection. Primary outcomes are quality of life and costs. Secondary outcomes are hospital stay, early and late morbidity, sick leave and surgical recurrence. In order to detect an effect size of 0.5 on the Inflammatory Bowel Disease Questionnaire at a 5% two sided significance level with a power of 80%, a sample size of 65 patients per treatment group can be calculated. An economic evaluation will be performed by assessing the marginal direct medical, non-medical and time costs and the costs per Quality Adjusted Life Year (QALY) will be calculated. For both treatment strategies a cost-utility ratio will be calculated. Patients will be included from December 2007.

Discussion: The LIR!C-trial is a randomized multicenter trial that will provide evidence whether infliximab treatment or surgery is the best treatment for recurrent distal ileitis in Crohn's disease.

Trial registration: Nederlands Trial Register NTR1150.

Figures

Figure 1
Figure 1
LIR!C-trial flowchart.

References

    1. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006;12 Suppl 1:S3–S9. doi: 10.1097/01.MIB.0000195385.19268.68.
    1. Baert F, Noman M, Vermeire S, Van AG, D' HG, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601–608. doi: 10.1056/NEJMoa020888.
    1. Rutgeerts P, Van AG, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology. 2004;126:1593–1610. doi: 10.1053/j.gastro.2004.02.070.
    1. Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A, D'Haens G, Kitis G, Cortot A, Prantera C, Marteau P, Colombel JF, Gionchetti P, Bouhnik Y, Tiret E, Kroesen J, Starlinger M, Mortensen NJ. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006;55 Suppl 1:i16–i35. doi: 10.1136/gut.2005.081950b.
    1. Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, Barakauskiene A, Villanacci V, Von HA, Warren BF, Gasche C, Tilg H, Schreiber SW, Scholmerich J, Reinisch W. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006;55 Suppl 1:i1–15. doi: 10.1136/gut.2005.081950a.
    1. Eshuis EJ, Polle SW, Slors JF, Hommes DW, Sprangers MA, Gouma DJ, Bemelman WA. Long-Term Surgical Recurrence, Morbidity, Quality of Life, and Body Image of Laparoscopic-Assisted vs. Open Ileocolic Resection for Crohn's Disease: A Comparative Study. Dis Colon Rectum. 2008
    1. Lowney JK, Dietz DW, Birnbaum EH, Kodner IJ, Mutch MG, Fleshman JW. Is there any difference in recurrence rates in laparoscopic ileocolic resection for Crohn's disease compared with conventional surgery? A long-term, follow-up study. Dis Colon Rectum. 2006;49:58–63. doi: 10.1007/s10350-005-0214-6.
    1. Bernklev T, Jahnsen J, Schulz T, Sauar J, Lygren I, Henriksen M, Stray N, Kjellevold O, Aadland E, Vatn M, Moum B. Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis. Eur J Gastroenterol Hepatol. 2005;17:1037–1045. doi: 10.1097/00042737-200510000-00006.
    1. Love JR, Irvine EJ, Fedorak RN. Quality of life in inflammatory bowel disease. J Clin Gastroenterol. 1992;14:15–19. doi: 10.1097/00004836-199201000-00005.
    1. Delaney CP, Kiran RP, Senagore AJ, O'Brien-Ermlich B, Church J, Hull TL, Remzi FH, Fazio VW. Quality of life improves within 30 days of surgery for Crohn's disease. J Am Coll Surg. 2003;196:714–721. doi: 10.1016/S1072-7515(03)00131-5.
    1. Duepree HJ, Senagore AJ, Delaney CP, Brady KM, Fazio VW. Advantages of laparoscopic resection for ileocecal Crohn's disease. Dis Colon Rectum. 2002;45:605–610. doi: 10.1007/s10350-004-6253-6.
    1. Dunker MS, Stiggelbout AM, van Hogezand RA, Ringers J, Griffioen G, Bemelman WA. Cosmesis and body image after laparoscopic-assisted and open ileocolic resection for Crohn's disease. Surg Endosc. 1998;12:1334–1340. doi: 10.1007/s004649900851.
    1. Maartense S, Dunker MS, Slors JF, Cuesta MA, Pierik EG, Gouma DJ, Hommes DW, Sprangers MA, Bemelman WA. Laparoscopic-assisted versus open ileocolic resection for Crohn's disease: a randomized trial. Ann Surg. 2006;243:143–149. doi: 10.1097/.
    1. Polle SW, Wind J, Ubbink DT, Hommes DW, Gouma DJ, Bemelman WA. Short-Term Outcomes after Laparoscopic Ileocolic Resection for Crohn's Disease. A Systematic Review. Dig Surg. 2006;23:346–357. doi: 10.1159/000097950.
    1. Young-Fadok TM, HallLong K, McConnell EJ, Gomez RG, Cabanela RL. Advantages of laparoscopic resection for ileocolic Crohn's disease. Improved outcomes and reduced costs. Surg Endosc. 2001;15:450–454. doi: 10.1007/s004640080078.
    1. Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, Sprangers MA, te VA, Verrips E. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol. 1998;51:1055–1068. doi: 10.1016/S0895-4356(98)00097-3.
    1. Group EQ. Euroqol: a new facility for the measurement of health-related quality of life. Health Policy. 1990:199–208.
    1. Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, Tompkins C. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96:804–810.
    1. Konig HH, Ulshofer A, Gregor M, Von TC, Reinshagen M, Adler G, Leidl R. Validation of the EuroQol questionnaire in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2002;14:1205–1215. doi: 10.1097/00042737-200211000-00008.
    1. Pallis AG, Mouzas IA, Vlachonikolis IG. The inflammatory bowel disease questionnaire: a review of its national validation studies. Inflamm Bowel Dis. 2004;10:261–269. doi: 10.1097/00054725-200405000-00014.
    1. Cohen J. In: Statitical Power Anlyses for the Behavioral Sciences. Associates NJIE, editor. Mahwah; 1988.
    1. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41:582–592. doi: 10.1097/00005650-200305000-00004.
    1. Hommes DW, Oldenburg B, van Bodegraven AA, van Hogezand RA, de Jong DJ, Romberg-Camps MJ, van der WJ, Dijkstra G. Guidelines for treatment with infliximab for Crohn's disease. Neth J Med. 2006;64:219–229.
    1. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52–65. doi: 10.1053/j.gastro.2006.11.041.
    1. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–333. doi: 10.1053/j.gastro.2005.11.030.
    1. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829–838.
    1. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232–1239. doi: 10.1136/gut.2006.106781.
    1. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357:228–238. doi: 10.1056/NEJMoa067594.
    1. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357:239–250. doi: 10.1056/NEJMoa062897.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe